(Q43658178)

25 November 2017

title

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients (English)

1 reference

25 November 2017

1 reference

1 reference

2

J L Blum

1 reference

25 November 2017

M A Villalona-Calero

1

1 reference

25 November 2017

S E Jones

3

1 reference

25 November 2017

S Diab

4

1 reference

25 November 2017

R Elledge

5

1 reference

25 November 2017

P Khoury

6

1 reference

25 November 2017

D Von Hoff

7

1 reference

25 November 2017

M Kraynak

8

1 reference

25 November 2017

J Moczygemba

9

1 reference

25 November 2017

P Kromelis

10

1 reference

25 November 2017

T Griffin

11

1 reference

25 November 2017

E K Rowinsky

12

1 reference

25 November 2017

publication date

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

12

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

605-614

1 reference

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Paclitaxel metabolites in human plasma and urine: Identification of 6α‐hydroxytaxol, 7‐epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric‐pressure chemical ionization mass spectrometry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

1 reference

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011181010669

7 January 2021

Identifiers

DOI

10.1023/A:1011181010669

1 reference

25 November 2017

1 reference